Abstract Details

Title The Role of 7T MRI to Assess Atrophy of the Subcortical Deep Gray Matter in Relapsing-remitting Multiple Sclerosis

Topic Multiple Sclerosis

Presentation(s) P2 - Poster Session 2 (8:00 AM-9:00 AM)

Poster/Presentation
Number 9-019

Objective To optimize an automated segmentation method for 7T deep grey matter (DGM) volume quantitation and assess its sensitivity for atrophy detection and relationship to DGM lesions and disability in relapsing-remitting MS (RRMS).

Background DGM atrophy and lesions are important elements of MS pathology. Prior data indicate 7T MRI affords improved DGM lesion detection and volume segmentation versus 3T.

Design/Methods 30 RRMS subjects [age (mean±SD) 44.0±11.3 years, EDSS score 2.0±1.4] and 15 age-/sex-matched healthy controls underwent 7T imaging with 3D MP2RAGE and FLAIR at 0.7 mm³ isotropic voxels, at baseline and 1-year. Applying the FSL-FIRST pipeline, we optimized pre-processing by combining two MP2RAGE inversion times and uniform T1-weighted images and introduced a constant real number for noise-suppressed MP2RAGE reconstruction. DGM structure [globus pallidus (GP), putamen, caudate and thalamus] volumes were normalized with the SIENAX normalization factor. Concurrent MP2RAGE T1-hypointensity and FLAIR T2-hyperintensity indicated DGM lesions. Brain white matter T2 lesion volume (T2LV) was expert-quantified. Unadjusted and age-adjusted group differences (two-sample t-tests and Spearman correlations) were assessed.

Results Total DGM volumes were lower in MS vs. controls (43.5 vs. 46.3 mL, p=0.034), varying by region and most pronounced in the caudate (9.0 vs. 9.9 mL, p=0.008). DGM volumes inversely correlated with EDSS (total DGM: r=-0.45, p=0.014; GP: r=-0.42, p=0.023; putamen: r=-0.44, p=0.016; caudate: r=-0.37, p=0.047) and T2LV (total DGM: r=-0.64, p<0.001; putamen: r=-0.48, p=0.009; thalamus: r=-0.76, p<0.001). DGM lesions were found in 77% (n=23) of MS subjects and no controls, with thalamic lesions being most prevalent (73%). Thalamic lesion volume correlated inversely with thalamic volume (r=-0.38, p=0.045). Analyses of longitudinal DGM lesion/atrophy associations at the 1-year timepoint are ongoing.

Conclusions We introduce an automated pre-processing method for 7T DGM volume segmentation, which shows a link between DGM atrophy and both white matter lesions and physical disability in RRMS. Furthermore, thalamic lesions are associated with thalamic atrophy.

Authors/Disclosures
Jonathan D. Zurawski, MD (Brigham & Women's Hospital) PRESENTER	The institution of Dr. Zurawski has received research support from The Race to Erase MS Foundation. The institution of Dr. Zurawski has received research support from Novartis Pharmaceuticals. The institution of Dr. Zurawski has received research support from I-Mab Biopharma . The institution of Dr. Zurawski has received research support from Elizabeth A. Kremer MS Research Foundation. The institution of Dr. Zurawski has received research support from Novartis.
Renxin Chu (Brigham & Women's Hospital)	Dr. Chu has nothing to disclose.
	No disclosure on file
Shahamat Tauhid, MD (Brigham & Women's Hospital)	Dr. Tauhid has nothing to disclose.
Brian C. Healy	The institution of Mr. Healy has received research support from Analysis Group. The institution of Mr. Healy has received research support from Bristol-Myers Squibb. The institution of Mr. Healy has received research support from Verily Life Sciences. The institution of Mr. Healy has received research support from Novartis. The institution of Mr. Healy has received research support from Merck Serono. The institution of Mr. Healy has received research support from Genzyme.
Howard L. Weiner, MD (Brigham and Women'S Hospital)	Dr. Weiner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Weiner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medday Pharmaceuticals. Dr. Weiner has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for vTv Therapeutics. Dr. Weiner has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Tiziana Life Sciences. Dr. Weiner has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for vTv Therapeutics. Dr. Weiner has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Medday Pharmaceuticals. Dr. Weiner has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for vTv Therapeutics. Dr. Weiner has stock in vTv Therapeutics. The institution of Dr. Weiner has received research support from National Institute of Health. The institution of Dr. Weiner has received research support from National MS Society. The institution of Dr. Weiner has received research support from Genzyme Corp. The institution of Dr. Weiner has received research support from Genentech, Inc. . The institution of Dr. Weiner has received research support from Verily Life Sciences LLC. The institution of Dr. Weiner has received research support from EMD Serono, Inc..
Rohit Bakshi, MD, F�鶹��ýӳ��	Dr. Bakshi has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for EMD Serono. Dr. Bakshi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. The institution of Dr. Bakshi has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Journal of Neuroimaging. The institution of Dr. Bakshi has received research support from Bristol Myers Squibb. The institution of Dr. Bakshi has received research support from EMD Serono. The institution of Dr. Bakshi has received research support from Novartis.

�鶹��ýӳ��

�鶹��ýӳ��